Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial

References

• Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005;141(3):325–330.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107(10):2504–2511.
   PubMed Web of Science ®Google Scholar
• Molloy K, Jonak C, Woei AJF, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770–779.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphomas version 2. 2020. [cited 2020 Jun 16]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
   Google Scholar
• Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30–iv40.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–3773.
   PubMed Web of Science ®Google Scholar
• Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–81.
   PubMed Web of Science ®Google Scholar
• Spaccarelli N, Rook AH. The use of interferons in the treatment of cutaneous T-cell lymphoma. Dermatol Clin. 2015;33(4):731–745.
   PubMed Web of Science ®Google Scholar
• Cho A, Jantschitsch C, Knobler R. Extracorporeal photopheresis-an overview. Front Med (Lausanne). 2018;5:236.
   PubMed Web of Science ®Google Scholar
• Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, et al. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int. 2014;2014:265840.
   PubMed Web of Science ®Google Scholar
• González-Rodríguez AP, Payer AR, Acebes-Huerta A, et al. Lenalidomide and chronic lymphocytic leukemia. Biomed Res Int. 2013;2013:932010.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget. 2017;8(14):24031–24044.
   PubMedGoogle Scholar
• González-Rodriguez AP, Villa-Álvarez M, Sordo-Bahamonde C, et al. NK cells in the treatment of hematological malignancies. J Clin Med. 2019;8(10):1557.
   Web of Science ®Google Scholar
• Nieto-Rementería N, Pérez-Yarza G, Boyano MD, et al. Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009;160(3):519–526.
   PubMed Web of Science ®Google Scholar
• Olek-Hrab K, Maj J, Chmielowska E, et al. Methotrexate in the treatment of mycosis fungoides - a multicenter observational study in 79 patients. Eur Rev Med Pharmacol Sci. 2018;22(11):3586–3594.
   PubMed Web of Science ®Google Scholar
• Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol. 2016;12(12):731–742.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Pizzorni C, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60(8):729–735.
   PubMed Web of Science ®Google Scholar
• Vergne P, Liagre B, Bertin P, et al. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J Rheumatol. 1998;25(3):433–440.
   PubMed Web of Science ®Google Scholar
• Walsdorfer U, Christophers E, Schröder JM. Methotrexate inhibits polymorphonuclear leucocyte chemotaxis in psoriasis. Br J Dermatol. 1983;108(4):451–456.
   PubMed Web of Science ®Google Scholar
• Kelly-Sell MJ, Kim YH, Straus S, et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol. 2012;87(4):354–360.
   PubMed Web of Science ®Google Scholar
• Roger T, Lugrin J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood. 2011;117(4):1205–1217.
   PubMed Web of Science ®Google Scholar
• Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010;28(S1):3–S20.
   Web of Science ®Google Scholar
• Kroesen M, Gielen P, Brok IC, et al. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;5(16):6558–6572.
   PubMed Web of Science ®Google Scholar
• Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112(8):3082–3087.
   PubMed Web of Science ®Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–3765.
   PubMed Web of Science ®Google Scholar
• Foss F, Duvic M, Lerner A, et al. Clinical efficacy of romidepsin in tumor stage and folliculotropic mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016;16(11):637–643.
   PubMed Web of Science ®Google Scholar
• Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res. 2012;18(18):5051–5060.
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16(5):1520–1531.
   PubMed Web of Science ®Google Scholar
• Ferenczi K, Fuhlbrigge RC, Pinkus J, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119(6):1405–1410.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204.
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Co., Ltd. New drug application approval for Poteligeo® (mogamulizumab) injection in Japan, a therapeutic antibody for adult T-cell leukemia-lymphoma (ATL) [press release]. 2012. [cited 2017 Sep 25]. Available from: http://www.kyowa-kirin.com/news_releases/2012/e20120330_04.html.
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Approval for additional indication for PTCL and CTCL of Mogamulizumab [press release]. 2014. [cited 2016 Feb 8]. Available from: http://www.kyowa-kirin.com/news_releases/2014/e20140317_01.html.
   Google Scholar
• Kyowa Kirin, Inc. Poteligeo® (mogamulizumab-kpkc) injection, for intravenous use [prescribing information]. 2018. [cited 2018 Sep 13]. Available from: https://www.poteligeohcp.com/assets/files/full-prescribing-information.pdf.
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Kyowa Kirin announces Poteligeo® receives marketing authorisation in Europe for the treatment of mycosis fungoides and Sézary syndrome [press release]. 2018. [cited 2020 Mar 23]. Available from: https://www.kyowakirin.com/media_center/news_releases/2018/e20181126_01.html.
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin receives the partial change approval of Poteligeo® in Japan [press release]. 2018. [cited 2020 Jun 12]. Available from: https://www.kyowakirin.com/media_center/news_releases/2018/e20180821_01.html.
   Google Scholar
• Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10(16):5494–5500.
   PubMed Web of Science ®Google Scholar
• Duvic M, Evans M, Wang C. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174.
   PubMed Web of Science ®Google Scholar
• Kitadate A, Ikeda S, Abe F, et al. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas. Haematologica. 2018;103(1):126–135.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–2607.
   PubMed Web of Science ®Google Scholar